Feature | September 05, 2012 | Joost Nuyttens, M.D., Ph.D.

SBRT Treatment for Central Lung Lesions

New research examines the effectiveness of using the CyberKnife system to treat cancer in the difficult central lung area

A CyberKnife treatment plan for lung cancer.

A CyberKnife treatment plan for lung cancer.

The preferred treatment for patients with operable lung cancer is surgical resection. However, many lung cancer patients whose tumors are technically resectable have other medical problems, such as chronic obstructive pulmonary disease, which make it difficult to endure lung cancer surgery. Until the last decade these patients were treated with conventional radiotherapy, but more recently stereotactic body radiotherapy (SBRT), or the accurate delivery of high doses of radiation over a short period of time, has emerged as an alternative treatment.

SBRT has been shown to be effective in the treatment of lesions in the peripheral region of the lungs.[1] Extending SBRT to the central lung is much more complicated. SBRT delivered to lesions located within 2 cm of the primary central airways of the lung can result in pneumonia, pericardial effusion, hemoptysis or even death.[2] Given these risks, it would be understandable if centers shied away from treating patients with central lesions with SBRT.

Observing this trend, and in light of features available with the CyberKnife SBRT system, the Erasmus MC – Daniel den Hoed Cancer Center in Rotterdam launched a study in July 2006 focused specifically on the use of SBRT to treat central lung tumors. The study, "Outcome of Four-Dimensional Stereotactic Radiotherapy for Centrally Located Lung Tumors," reported on 56 patients (39 with primary lung cancer and 17 with metastatic tumors) treated with the CyberKnife system.[3] All of these patients were ineligible for surgery or chemotherapy, refused surgery or chemotherapy, or had an inoperable tumor.

Unlike other SBRT treatment methods, the CyberKnife system is equipped with a technology called the Synchrony respiratory tracking system, making it uniquely suited to treating central lung tumors. The Synchrony system correlates the position of the chest as it rises and falls during breathing with the position of the tumor as revealed with the CyberKnife's image-guidance system. This allows Synchrony to guide the radiation beam so that it remains locked onto the moving tumor, thus allowing clinicians to significantly reduce treatment volumes and spare healthy tissue without the need for gating, breath holding, body frames or abdominal compression.

The treatment accuracy of the Synchrony system allows the margins necessary to account for uncertainty in target position to be narrow (at Erasmus MC, the total clinical error is routinely less than 1.5 mm), so that high SBRT doses can be delivered with relatively low toxicity to the central chest region. Keeping toxicity low is especially important for these patients, many of whom are treated with SBRT precisely because they are unable to withstand the rigors of surgery.

Study Details
The study found that tracking and correcting for respiratory motion with CyberKnife SBRT allowed clinicians to deliver treatment to the central lung with minimal toxicity, sparing surrounding healthy tissue, while also providing high levels of tumor control. In fact, the toxicity was among the lowest reported to date for central lung lesions.

Local tumor control was 91 percent for the entire group at one year and 76 percent for the entire group at two years. For the patients treated with at least 50 Gy, two-year local control was 85 percent. The overall two-year survival rate was 60 percent. The analysis of toxicity rates demonstrated that there were no serious complications (especially no life-threatening/disabling or fatal toxicities).

Historically, research has shown that even SBRT doses as low as 40 Gy can cause significant complications when treating lesions in the central chest. These findings point to the critical importance of careful treatment planning, accurate patient setup and precise radiation delivery.

For this study, the patients benefited from the team’s ability to use small error margins around the clinical target volume, with the CyberKnife system. The small margins could only be achieved with the Synchrony system.




Joost J. Nuyttens, M.D., Ph. D., did post-graduate medical specialty training including radiotherapy at the University of Ghent in Belgium and advanced radiation oncology training at the Medical University of South Carolina. He was a research fellow at the William Beaumont Hospital in Detroit. Since 2001, Nuyttens has been working as a radiation oncologist in the department of radiation oncology at Daniel Den Hoed Cancer Centre, Rotterdam, The Netherlands, with a special focus on thoracic, digestive and gynecologic cancers. For the past six years, he has been using CyberKnife robotic radiosurgery to treat early stage NSCLC and isolated lung metastases.?
References:?1 Brown WT, Wu X, Fayad F, et al. "Application of robotic stereotactic radiotherapy to peripheral stage I non-small cell lung cancer with curative intent." Clin Oncol (R Coll Radiol) 2009;21:623-631; Vahdat S, Oermann EK, Collins SP, et al. "CyberKnife radiosurgery for inoperable stage IA non-small cell lung cancer: 18F-fluorodeoxyglucose positron emission tomography/computed tomography serial tumor response assessment." J Hematol Oncol 2010;3:6; van der Voort van Zyp NC, Prevost JB, Hoogeman MS, et al. "Stereotactic radiotherapy with real-time tumor tracking for non-small cell lung cancer: clinical outcome." Radiother Oncol 2009;91:296-300; van der Voort van Zyp NC, van der Holt B, van Klaveren RJ, et al. "Stereotactic body radiotherapy using real-time tumor tracking in octogenarians with non-small cell lung cancer." Lung Cancer 2010;69:296-301
2 Timmerman R, McGarry R, Yiannoutsos C, et al. "Excessive toxicity when treating central tumors in a phase II study of stereotactic body radiation therapy for medically inoperable early-stage lung cancer." J Clin Oncol 2006;24:4833-4839
3 Nuyttens JJ, van der Voort van Zyp NC, Praag J, Aluwini S, van Klaveren RJ, Verhoef C, Pattynama PM, Hoogeman MS. "Outcome of four-dimensional stereotactic radiotherapy for centrally located lung tumors." Radiother Oncol 2012, Mar;102(3):383-7

Related Content

Mevion Receives 510(k) Clearance for Hyperscan Pencil Beam Scanning Proton Therapy
Technology | Proton Therapy | January 04, 2018
Mevion Medical Systems has received U.S. Food and Drug Administration (FDA) 510(k) clearance for the Mevion S250i...
Study Compares Radiosurgery and Whole-Brain Radiation in Lung Cancer Patients With Multiple Brain Metastases
News | Radiation Therapy | January 03, 2018
Although targeted therapies have produced dramatic advances in the ability to control some types of advanced lung...
MEDraysintell Downgrades Proton Therapy Market Projection for 2030
News | Proton Therapy | January 02, 2018
MEDraysintell recently downgraded its projection for proton therapy rooms expected to be operational in 2030 from 1,200...
California US Oncology Network Centers Adopt Xoft Electronic Brachytherapy System for Early-Stage Non-Melanoma Skin Cancer
News | Brachytherapy Systems | January 02, 2018
iCAD Inc. announced that its Xoft Axxent Electronic Brachytherapy (eBx) System is now available at two California-based...
Blue Phantom System Used for Acceptance of First European Varian Halcyon Machine
News | Radiation Therapy | January 02, 2018
IBA (Ion Beam Applications S.A.) announced in November the acceptance and beam model validation of the first Varian...
Study Finds Link Between Breast Cancer Treatments and Cellular Aging Markers
News | Women's Health | January 02, 2018
January 2, 2018 — A new study found women who had received chemotherapy and/or...
ACR Appropriateness Criteria Adds and Revises Topics for December 2017
News | Clinical Decision Support | December 29, 2017
December 29, 2017 — Radiologists can enhance the quality and effectiveness of care with the newest release of the ACR
FDA Clears GammaPod Stereotactic Radiotherapy System for Breast Cancer Treatment
Technology | Stereotactic Body Radiation Therapy (SBRT) | December 22, 2017
The U.S. Food and Drug Administration (FDA) has cleared the new GammaPod noninvasive stereotactic radiotherapy system...
RaySearch Launches RayCare Oncology Information System

Image courtesy of RaySearch Laboratories

Technology | Oncology Information Management Systems (OIMS) | December 22, 2017
RaySearch announced the first release of RayCare, a new oncology information system (OIS) designed to connect the...
RaySearch Releases RayStation 7 Radiotherapy Treatment Planning System
Technology | Treatment Planning | December 19, 2017
RayStation 7, the latest release of RaySearch’s radiation therapy treatment planning system, adds new functionality and...
Overlay Init